

Telemedicine and Remote Patient Monitoring for Improving Healthcare Access and Clinical Outcomes: A Systematic Review

Rohan Mody¹, Solanki Rutvij Bharatsinh², Sherasiya Anjilabanu Ayubhbhai³

¹MBBS, GMERS Medical College, Sola, Ahmedabad, Gujarat, India.

²MBBS, Gujarat Adani Institute of Medical Sciences, Bhuj, Gujarat, India.

³MBBS, C. U. Shah Medical College, Surendranagar, Gujarat, India.

Received: 15-09-2026 / Revised: 01-10-2026 / Accepted: 06-10-2026

Corresponding author: Dr. Sherasiya Anjilabanu Ayubhbhai

Conflict of interest: Nil

Abstract

Background: Telemedicine and remote patient monitoring (RPM) can extend clinical contact beyond conventional visits, potentially improving access, physiologic control and early detection of deterioration. Effects on hospitalization and other hard outcomes, however, have varied across trials.

Objectives: To evaluate the effect of telemedicine and RPM on healthcare access, clinical outcomes, hospitalization, mortality, physiologic control and patient experience across chronic disease populations.

Methods: A PRISMA-structured search framework covering PubMed, Scopus, Embase and Cochrane was used. Randomized and prospective comparative studies of clinician-linked telemedicine/RPM were eligible. RoB 2 was used for randomized trials and Newcastle-Ottawa/ROBINS-I principles for non-randomized evidence. A random-effects meta-analysis pooled binary readmission/hospitalization data from three clinically comparable randomized trials.

Results: The direction of benefit depended strongly on intervention intensity and the presence of an actionable clinical response pathway. The exploratory pooled risk of readmission/hospitalization across Tele-HF, BEAT-HF and a COPD telemonitoring trial was RR 1.03 (95% CI 0.96–1.11; $I^2=0\%$), indicating no clear reduction in this subset. In contrast, TIM-HF2 reduced days lost to cardiovascular hospitalization or death and reduced all-cause mortality, while broader meta-analyses report modest improvements in blood pressure, HbA1c and selected utilization endpoints. Access gains were tempered by digital exclusion and variable uptake.

Conclusion: Telemedicine and RPM are not a uniform intervention. Programs that combine reliable measurement, rapid clinical interpretation, medication/treatment action and patient engagement appear more effective than passive data transmission. Equity, interoperability, burden and sustainable reimbursement should be treated as core components of effectiveness.

Keywords: Telemedicine; Remote Patient Monitoring; Healthcare Access; Hospitalization; Chronic Disease; Digital Health; Meta-Analysis.

DOI: 10.25258/ijcpr.18.9.176

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

Telemedicine encompasses synchronous video or telephone care, asynchronous messaging, store-and-forward review and technology-enabled clinical services delivered at a distance. Remote patient monitoring adds repeated transmission of physiologic or symptom data such as blood pressure, oxygen saturation, body weight, glucose, heart rate or spirometry. Together these approaches are intended to reduce geographic and temporal barriers, permit earlier intervention and support chronic disease self-management [1-2].

The potential value is particularly important for patients who require frequent follow-up but face travel, disability, and workforce or specialist-access

constraints. Telehealth can move selected encounters into the home and create a continuous stream of information rather than relying on episodic clinic measurements. However, expanding contact is not synonymous with improving outcomes. If incoming data are not reviewed promptly, thresholds are poorly calibrated, or clinicians cannot act on alerts, monitoring may add workload without changing care.

Heart failure provides a useful example of the controversy. Large trials have produced different results: Tele-HF and BEAT-HF did not significantly reduce readmission, whereas the structured TIM-HF2 program reduced days lost to

cardiovascular hospitalization or death and lowered all-cause mortality [3-5]. These differences suggest that the intervention architecture—monitoring frequency, clinician staffing, escalation rules, adherence and integration with disease management—may be more important than the label “telemonitoring.”

Similar heterogeneity is seen in chronic obstructive pulmonary disease (COPD), diabetes and hypertension. Some programs improve physiologic targets or reduce acute care, while others show neutral utilization results. A broad systematic review and meta-analysis of interactive RPM found reductions in mortality and modest improvements in blood pressure and HbA1c but substantial heterogeneity for several outcomes [2]. A newer randomized-trial synthesis reported a modest reduction in the proportion hospitalized, while evidence certainty remained low for some utilization outcomes [6].

Access also has an equity dimension. Video visits may improve access for rural patients with broadband and devices but disadvantage people with limited digital literacy, language barriers, sensory impairment, unstable housing or low-quality connectivity. The rapid pandemic expansion of telemedicine demonstrated both reach and sociodemographic differences in modality use [7]. The present review therefore evaluates access and clinical outcomes together rather than treating digital availability as equivalent to equitable access.

Objective and PICO:

The PICO question was: Population: adults with chronic diseases or ongoing outpatient care needs; Intervention: telemedicine and/or clinician-linked RPM; Comparator: usual in-person care or non-monitored usual care; Outcomes: healthcare access, hospitalization/readmission, mortality, physiologic disease control, quality of life, patient satisfaction and service utilization. The primary aim was to determine which models are associated with clinically meaningful benefit and to distinguish effective remote care from passive monitoring.

Methods

The review was organized according to PRISMA 2020 [1]. Search concepts were developed for PubMed/MEDLINE, Scopus, Embase and CENTRAL from inception through 20 September 2026. The search combined telemedicine terms (telehealth, virtual care, video consultation), RPM terms (remote monitoring, telemonitoring, home monitoring, connected device) and clinical outcomes (hospitalization, readmission, mortality, blood pressure, HbA1c, quality of life and access).

Reference lists of major systematic reviews were used for citation chasing [2,6]. Randomized controlled trials, cluster-randomized trials and prospective comparative studies were eligible when the intervention involved patient-clinician remote interaction or transmission of patient-generated health data with a defined care pathway. Studies were excluded if the digital component was limited to one-way educational content without clinical interaction, if monitoring was purely investigational with no feedback pathway, or if the report lacked a comparator and clinically interpretable outcomes.

Data extraction captured disease, setting, inclusion criteria, intervention modality, monitoring frequency, clinical response mechanism, duration, adherence, readmission/hospitalization, mortality, physiologic outcomes, and quality of life, satisfaction, and access measures. Importantly, the response pathway was coded as passive, protocolized non-real-time, or active clinician-led escalation because this characteristic plausibly modifies effectiveness.

Randomized trials were appraised with RoB 2. Non-randomized comparative evidence was assessed using ROBINS-I/NOS principles, focusing on baseline confounding, outcome ascertainment and missing data. Blinding participants is rarely feasible in telehealth studies; therefore, objective hospitalization and mortality outcomes were given greater weight than unblinded self-reported outcomes when judging overall certainty.

For the exploratory meta-analysis, three trials reported a binary proportion experiencing all-cause readmission or disease-related hospitalization in intervention and control groups over approximately 6–12 months [3,4,7,8].

Risk ratios were pooled on the log scale using a DerSimonian-Laird random-effects model. TIM-HF2 used a rate-based composite of days lost rather than a simple binary hospitalization proportion and was therefore synthesized separately to preserve endpoint validity [5].

PRISMA flow and study selection: The review was organized according to PRISMA 2020. The final curated evidence set contained 14 primary studies/reports that satisfied the prespecified clinical eligibility criteria; 3 contributed directly to the primary quantitative synthesis. Database-specific identification and duplicate-removal counts are intentionally shown as verification fields rather than invented values and should be populated from the final exported search histories before submission [1].

Table 1: PRISMA 2020 study-selection status

PRISMA stage	Record category	Count
Identification	PubMed / Scopus / Embase / Cochrane records	Verify From Final Database Export
Deduplication	Unique records after reference-manager deduplication	Verify From Final Database Export
Screening	Title/abstract exclusions	Verify From Final Database Export
Eligibility	Full texts assessed	Verify From Final Database Export
Included	Primary studies/reports in qualitative synthesis	14
Meta-analysis	Studies in primary quantitative synthesis	3

Results

Study characteristics

Table 2: Representative Telemedicine and remote monitoring trials.

Study	Condition	N	Intervention	Principal endpoint	Summary
Chaudhry 2010 Tele-HF [3]	Heart failure	1,653	Telephone-based daily symptom/weight reporting	Readmission/death	Neutral primary outcome
Ong 2016 BEAT-HF [4]	Heart failure	1,437	Predischarge education + telemonitoring + calls	180-day readmission	No significant reduction
Koehler 2018 TIM-HF2 [5]	Heart failure	1,538 analysis set	Daily multivital RPM + 24/7 telemedical center	Days lost / mortality	Ratio 0.80; mortality HR 0.70
Andersen 2024 [8]	COPD	222	Home telemonitoring	AECOPD hospitalization	31/110 vs 37/112 hospitalized
Vianello 2016 [9]	COPD	334	Home monitoring + clinical response	Readmissions/hospital use	Lower readmission incidence
Pletcher 2022 [10]	Hypertension	2,101	Smartphone BP self-monitoring program	BP control	No superiority for primary BP outcome
Crowley 2022 [11]	Diabetes	~590	Comprehensive telehealth diabetes management	HbA1c / risk factors	Improved glycemic control in selected groups

Meta-analysis of readmission/hospitalization: The three trials with compatible binary outcomes yielded a pooled RR of 1.03 (95% CI 0.96–1.11; $I^2=0\%$). Thus, in this deliberately narrow subset, remote monitoring did not clearly reduce the probability that a patient experienced readmission or hospitalization. The estimate should not be generalized to all telemedicine programs because intervention intensity and disease context varied, and effective programs such as TIM-HF2 used different primary outcome definitions.




Figure 1: Random-effects meta-analysis of binary readmission/hospitalization. Pooled RR 1.03 (95% CI 0.96–1.11); $I^2=0\%$.

Table 3: Exploratory meta-analysis of readmission/hospitalization.

Study	RR	95% CI	Intervention events/N	Control events/N
Tele-HF, 2010	1.04	0.94–1.15	407/826	392/827
BEAT-HF, 2016	1.03	0.93–1.15	363/715	355/722
Andersen et al., 2024 COPD	0.85	0.57–1.27	31/110	37/112
Pooled	1.03	0.96–1.11	$I^2=0\%$	Random effects

Mortality, disease control, access and experience: The heart-failure evidence demonstrated important program-level heterogeneity. Tele-HF did not reduce readmission or death, and adherence to daily telephone reporting declined over time [3]. BEAT-HF similarly failed to reduce 180-day readmission despite a multicomponent transitional-care program [4]. By contrast, TIM-HF2 used daily transmission of multiple physiologic variables to a staffed telemedical center with defined intervention capability and reduced the proportion of days lost to unplanned cardiovascular hospitalization or death (ratio 0.80, 95% CI 0.65–1.00) and all-cause mortality (HR 0.70, 95% CI 0.50–0.96) [5].

Across chronic diseases, a 2022 systematic review of interactive RPM found lower all-cause mortality (RR 0.71, 95% CI 0.56–0.89) and modest average improvements in systolic blood pressure and HbA1c, although heterogeneity for physiologic outcomes was very high [2]. A 2025 review restricted to more recent randomized trials reported a modest reduction in the proportion hospitalized

(RR approximately 0.86) and shorter length of stay, with low certainty for some endpoints [6]. These results are compatible with the idea that RPM is more effective for disease control and early escalation than for uniformly preventing every hospitalization.

COPD trials were mixed. Some home telemonitoring programs reduced readmission incidence or acute-care use, whereas others showed limited effect on hospitalization. Differences in exacerbation definitions, baseline severity, monitoring burden and access to respiratory teams make direct comparison difficult [8,9]. In hypertension, technology can improve measurement frequency and support titration, but a smartphone-based self-monitoring RCT did not demonstrate superiority for its primary BP outcome when both groups received substantial usual care [10].

Access outcomes were generally favorable when telemedicine substituted for travel and enabled specialist contact, but access was conditional on

technology availability and user capability. Reviews of pandemic-era telehealth reported differences in video versus telephone use by age, race/ethnicity, socioeconomic status and digital resources [7]. Consequently, a service can increase total visit availability while still creating a digital access gradient. Patient satisfaction was commonly high among users who completed programs, yet

uptake and persistence varied. Attrition is clinically relevant because benefits depend on repeated engagement. Device burden, charging, connectivity, alert fatigue and the perceived usefulness of clinician feedback influenced sustained participation. Programs that returned actionable advice were generally more acceptable than those perceived as simple surveillance [12].

Table 4: Risk-of-bias summary for key comparative evidence.

Study/evidence	Randomization	Missing data	Outcome measurement	Overall	Comments
Tele-HF [3]	Low	Low	Low	Some concerns	Adherence declined; intervention relied on patient-initiated daily calls
BEAT-HF [4]	Low	Low	Low	Low–some concerns	Robust multicenter design; complex intervention
TIM-HF2 [5]	Low	Low	Low	Low	Well-defined 24/7 response pathway; strong endpoint ascertainment
COPD telemonitoring [8,9]	Some concerns	Some concerns	Low	Some concerns	Smaller samples; differing exacerbation definitions
Hypertension/diabetes telehealth [10,11]	Low–some concerns	Some concerns	Low	Some concerns	Behavioral cointerventions and engagement influence effects

Discussion

The central finding is that telemedicine and RPM should not be interpreted as a single therapeutic exposure. The technology is a delivery mechanism; clinical effectiveness arises from the surrounding care model. Programs that merely collect measurements may be neutral, while programs that link reliable measurements to timely interpretation and treatment adjustment can improve outcomes. The contrast between Tele-HF/BEAT-HF and TIM-HF2 illustrates this distinction [13-15].

The exploratory meta-analysis found no clear reduction in the binary probability of hospitalization across three selected trials. This neutral result is informative rather than contradictory to the broader literature. Hospitalization is influenced by disease severity, local admission thresholds and competing risks, and remote monitoring can sometimes appropriately increase early admissions by detecting deterioration. Rate-based outcomes, days alive out of hospital, severity of events and mortality may therefore capture different dimensions of value.

Physiologic endpoints appear more consistently responsive. Blood pressure and HbA1c can improve when repeated home measurements are coupled with coaching, medication adjustment and feedback [2]. Yet very high heterogeneity in meta-analyses indicates that average effects conceal wide variation in program design. Future reviews should

classify interventions by clinical action intensity rather than by device type alone.

Healthcare access is both a benefit and a possible source of inequity. Remote visits can reduce travel time, missed work and geographic barriers. For rural or mobility-limited patients, these changes are meaningful outcomes even when hospitalization is unchanged. However, video-first systems may exclude patients who lack broadband, appropriate devices, private space, interpreter support or digital literacy. Telephone options, device-lending programs, accessible interfaces and community digital support can reduce this risk [7].

Safety and workload require careful measurement. RPM creates continuous data streams and can shift work from scheduled visits to asynchronous review. Poorly calibrated thresholds generate false alerts and clinician fatigue; overly permissive thresholds miss deterioration. Programs need staffing models, triage protocols, response-time expectations and documentation standards. Automated summarization may help but introduces another layer of algorithmic risk.

Economic value depends on who bears device, connectivity and staffing costs and whether avoided visits or admissions offset those costs. Trials frequently report clinical outcomes without full cost-effectiveness analyses. Reimbursement policies can also shape implementation: fee-for-service incentives may encourage monitoring volume, whereas capitated systems may focus more

on avoidable utilization. Comparative economic studies should report technology, personnel, training and patient-incurred costs.

Interoperability is another determinant of scalability. Data that reside in separate vendor portals force clinicians to switch context and can fragment the record. Effective RPM should integrate with the electronic health record, produce interpretable trends rather than raw streams, and preserve traceability of alerts and actions. Standards for device validation and cybersecurity are especially important when measurements are used for medication changes.

Future trials should adopt pragmatic designs with diverse populations and explicitly measure digital inclusion, adherence, response latency, medication changes, adverse events, and caregiver burden and clinician workload. Patient-centered endpoints such as days at home, time to treatment, symptom burden and confidence in self-management may capture value that a single readmission endpoint misses.

Components of effective remote-care programs:

The evidence suggests that four components distinguish higher-value remote management from passive data collection: a valid measurement, reliable transmission, timely clinical interpretation and an actionable response. Failure at any stage weakens the intervention. A connected scale that transmits weight but is not reviewed until the next clinic visit offers little advantage over a paper diary. By contrast, a structured heart-failure program that integrates daily measurements with staffed review and medication or referral protocols can detect decompensation while there is still time to intervene [5].

Monitoring frequency should match the biology of the condition. Heart-failure weight, symptoms and vital signs can change within days, whereas HbA1c reflects months of glycemic exposure. Excessively frequent monitoring of a slowly changing variable can increase burden without improving decisions. Similarly, thresholds should account for baseline variability and measurement error. Personalized change-from-baseline alerts may be more useful than fixed population thresholds for some physiologic measures.

The human response layer is often the most expensive component. Programs may use nurses, pharmacists, physicians or centralized telemedical teams. The workforce model determines the maximum number of patients who can be safely monitored and the latency from alert to action. Studies should report staffing ratios, hours of coverage, escalation pathways and after-hours procedures because these factors are necessary for replication and cost estimation. Behavioral support

is another active ingredient. Remote monitoring can increase self-awareness, but repeated measurements without interpretation may cause anxiety or disengagement. Programs that explain trends, provide goal-directed feedback and reinforce medication or lifestyle plans can transform measurement into self-management [6]. This behavioral mechanism may explain why similar devices produce different outcomes in different trials.

Healthcare access, equity and the digital divide:

Access should be conceptualized as the ability to obtain appropriate care, not simply the availability of a video platform. Telemedicine can reduce travel, waiting and indirect costs, particularly for rural populations, people with mobility limitations and those who require frequent specialist review. It can also improve continuity after hospital discharge by creating planned contact during a vulnerable transition. These benefits are meaningful even if a trial is underpowered for mortality.

Yet digital delivery can introduce new barriers. Broadband instability, device ownership, data cost, digital literacy, hearing or visual impairment, limited English proficiency and lack of private space can affect both participation and the quality of an encounter. Older adults are not uniformly digitally excluded, but interfaces requiring multiple logins, pairing procedures or frequent software updates may reduce adherence. Equity-oriented programs should offer technical onboarding, multilingual instructions, accessibility features, telephone alternatives and loaned devices when needed [7].

Measurement equity is also relevant. Consumer devices may perform differently across skin tones, arrhythmias, body habitus or motion conditions. A remote program that depends on inaccurate home measurements can create systematic clinical errors. Devices used for treatment decisions should therefore have appropriate validation, and remote protocols should specify when an implausible value requires repeat measurement or in-person confirmation. Telemedicine may redistribute access between patient groups. A clinic that shifts routine follow-up online can free in-person slots for patients who require physical examination, but this only occurs if scheduling systems are intentionally redesigned. Hybrid care should therefore match modality to clinical need rather than forcing every patient into the same digital pathway.

Interpreting utilization outcomes and choosing endpoints: Hospitalization and readmission are attractive endpoints because they are objective and economically important, but they are not always straightforward indicators of telemonitoring success. Early detection may appropriately lead to hospital evaluation for a high-risk patient who

otherwise would have presented later and sicker. Conversely, some admissions are driven by social support, local practice patterns or comorbidity rather than the monitored disease. Trials should distinguish disease-specific from all-cause admissions and report emergency visits, length of stay, intensive-care use and days alive at home.

Composite endpoints can capture multiple dimensions but may be difficult to compare. TIM-HF2 used days lost to unplanned cardiovascular hospital admission or death, integrating frequency and duration of hospitalization with the competing risk of death [5]. This approach is informative but cannot be combined directly with a simple binary “any readmission” outcome without losing meaning. Meta-analyses should therefore resist forcing incompatible utilization measures into a single effect estimate.

Patient-reported outcomes deserve greater emphasis. Symptom burden, treatment confidence, convenience, caregiver strain and quality of life may improve even when hospitalization is unchanged. At the same time, remote monitoring can create surveillance burden or anxiety. Future trials should include validated measures of treatment burden and digital burden in addition to satisfaction, because satisfaction among completers can overlook patients who disengage early.

Implementation studies should also capture time to clinical response. A monitoring system that detects deterioration earlier but takes 48 hours to produce an action may not be clinically effective. Alert-to-review time, review-to-contact time and contact-to-treatment time can identify where a remote-care pathway fails and may be more actionable than a single final outcome.

Practical clinical framework for selecting telemedicine/RPM: For clinical services considering adoption, the first question should be whether remote information can change a decision before the next conventional encounter. Conditions with frequent measurable instability, such as heart failure or poorly controlled hypertension, are logical candidates when a timely response pathway exists. If there is no actionable decision, collecting additional data may increase burden without clinical value. Programs should map each monitored variable to a predefined action, responsible clinician and expected response time. Second, patient selection should consider both clinical risk and feasibility. Very low-risk patients may obtain little incremental benefit from intensive monitoring, whereas extremely unstable patients may require in-person assessment that home technology cannot replace. A middle group—high enough risk to benefit from early detection but clinically stable enough for home management—may yield the greatest value. Selection should also

incorporate patient preference, caregiver support, sensory or cognitive limitations and connectivity.

Third, services should establish explicit escalation pathways. Alerts should be stratified by severity, with clear thresholds for repeat measurement, telephone assessment, medication change, urgent clinic review or emergency referral. Acknowledgement and closure of alerts should be auditable. Safety metrics should include unreviewed alerts, delayed responses, technical failures and emergency events occurring despite reassuring remote data.

Fourth, programs should define the relationship between remote and in-person care. Telemedicine works best as part of a hybrid pathway rather than as an absolute replacement. Physical examination, diagnostic procedures and complex shared decision-making may still require in-person contact. Conversely, stable follow-up, medication review and review of home measurements can often be delivered remotely. A modality-matching strategy can preserve convenience while avoiding inappropriate substitution.

Finally, implementation should be evaluated as a quality-improvement process after launch. Dashboards can track enrollment, activation, measurement adherence, alert volume, response time, hospital use, patient experience and equity indicators. Programs that do not demonstrate value should be redesigned or de-implemented rather than maintained because the technology is available. This learning-health-system approach is especially important because devices, connectivity and patient expectations evolve quickly.

Limitations

The literature is clinically heterogeneous, and intervention labels often conceal substantial differences in monitoring intensity and response pathways. The binary hospitalization meta-analysis included only three trials with sufficiently comparable data and should be considered exploratory. Some access studies were conducted during pandemic conditions and may not represent mature hybrid care. Finally, exact platform-specific database hit counts require regeneration from the submitting institution’s search exports before submission; this draft intentionally avoids invented PRISMA identification numbers.

Conclusion

Telemedicine and RPM can improve access and selected clinical outcomes, but effectiveness is driven by the care process built around the technology. Passive monitoring is not equivalent to active remote management. Structured programs with validated measurements, timely clinician response, clear escalation pathways and sustained

patient engagement show the most persuasive benefit. Implementation should be designed for digital equity, manageable workload, interoperability and measurable patient value.

References

- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement. *BMJ*. 2021; 372:n71. doi:10.1136/bmj.n71. PMID:33782057.
- Leo DG, Buckley BJR, Chowdhury M, et al. Interactive remote patient monitoring devices for managing chronic health conditions: systematic review and meta-analysis. *J Med Internet Res*. 2022;24(11):e35508. doi:10.2196/35508. PMID:36326818.
- Chaudhry SI, Mattern JA, Curtis JP, et al. Telemonitoring in patients with heart failure. *N Engl J Med*. 2010;363:2301-2309. doi:10.1056/NEJMoa1010029. PMID:21080835.
- Ong MK, Romano PS, Edgington S, et al. Effectiveness of remote patient monitoring after discharge of hospitalized patients with heart failure: the BEAT-HF randomized clinical trial. *JAMA Intern Med*. 2016;176(3):310-318. doi:10.1001/jamainternmed.2015.7712. PMID:26857383.
- Koehler F, Koehler K, Deckwart O, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2). *Lancet*. 2018;392(10152):1047-1057. doi:10.1016/S0140-6736(18)31880-4. PMID:30153985.
- Smedslund G, Østerås N, Hestevik CH. Effects of Remote Patient Monitoring on Health Care Utilization in Patients With Noncommunicable Diseases: Systematic Review and Meta-Analysis. *JMIR Mhealth Uhealth*. 2025;13:e68464. doi:10.2196/68464. PMID:41032865.
- Colburn DA. The Impact of Telehealth Expansion on Health Care Utilization, Access, and Outcomes During the Pandemic: A Systematic Review. *Telemed J E Health*. 2024;30(5):1401-1410. doi:10.1089/tmj.2023.0440. PMID:38100326.
- Andersen FD, Trolle C, Pedersen AR, Køpfler ML, Børgesen S, Jensen MS, Hyldgaard C. Effect of telemonitoring on readmissions for acute exacerbation of chronic obstructive pulmonary disease: a randomized clinical trial. *J Telemed Telecare*. 2024;30(9):1417-1424. doi:10.1177/1357633X221150279. PMID:36683440.
- Vianello A, Fusello M, Gubian L, et al. Home telemonitoring for patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial. *BMC Pulm Med*. 2016;16(1):157. doi:10.1186/s12890-016-0321-2. PMID:27876029.
- Pletcher MJ, Fontil V, Modrow MF, et al. Effectiveness of Standard vs Enhanced Self-measurement of Blood Pressure Paired With a Connected Smartphone Application: A Randomized Clinical Trial. *JAMA Intern Med*. 2022;182(10):1025-1034. doi:10.1001/jamainternmed.2022.3355. PMID:35969408.
- Crowley MJ, Tarkington PE, Bosworth HB, et al. Effect of a Comprehensive Telehealth Intervention vs Telemonitoring and Care Coordination in Patients With Persistently Poor Type 2 Diabetes Control: A Randomized Clinical Trial. *JAMA Intern Med*. 2022;182(9):943-952. doi:10.1001/jamainternmed.2022.2947. PMID:35877092.
- Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. *Lancet*. 2011; 377:658-666. doi:10.1016/S0140-6736(11)60101-3. PMID:21315441.
- Koehler F, Koehler K, Prescher S, et al. Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trial. *Lancet Digit Health*. 2020;2(1):e16-e24. doi:10.1016/S2589-7500(19)30195-5. PMID:33328035.
- Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016;355:i4919. doi:10.1136/bmj.i4919. PMID:27733354.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986; 7(3):177-188. doi:10.1016/0197-2456(86)90046-2. PMID:3802833.